Ixazomib action and efficacy

Ixazomib is indicated for use in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one prior therapy. Ixazomib is not recommended for maintenance treatment or in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma outside of controlled clinical trials.

Ixazomib is an N-terminal dipeptidyl leucine boronic acid that reversibly inhibits the CT-L proteolytic (β5) site of the proteasome. At higher concentrations, ixazomib also appears to inhibit the proteolytic β1 and β2 subunits and induce the accumulation of ubiquitinated proteins.

Clinical trials have shown that ixazomib is more effective than the experimental drug in treating multiple myeloma. In clinical trials, ixazomib achieved responses faster than the other treatment group. Ixazomib delayed disease progression longer than the other treatment groups.

Patients in the trialwith ixazomib had higher levels of positive responses compared with other treatment groups. Ixazomib works very well in patients with high-risk cytogenetics, stage III disease, and patients 75 years and older. Treatment with ixazomib is more effective in slowing the progression of multiple myeloma. The delay in time to first progression was : 5.9 months longer in the ixazomib group compared with the placebo group. (20.6 for ixazomib and 14.7 for placebo). Patients with high-risk cytogenetics had an extended period of 11.7 months. (Ixazomib 21.4 months, placebo 9.7 months). III stage patients are 8.3 months old. (ixazomib18.4months, placebo10.1months). 75For patients over years old, it was 5.4 months. (ixazomib18.5months, placebo13.1months). The retail price of Lucius Pharmaceuticals in Laos is about 900 yuan for 4mg*3 tablets. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.